Heron Therapeutics (HRTX)
(Delayed Data from NSDQ)
$3.24 USD
-0.07 (-2.11%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.23 -0.01 (-0.31%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HRTX 3.24 -0.07(-2.11%)
Will HRTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRTX
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
HRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
United Therapeutics (UTHR) Completes Enrolment in IPF Study
New Strong Buy Stocks for July 11th
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
Other News for HRTX
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash Reserves
Heron Therapeutics initiated with bullish view at Rodman & Renshaw
Northland Securities Reaffirms Their Buy Rating on Heron Therapeutics (HRTX)
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")